Similarly, Sholl et al [17] reported that EGFR mutations were significantly associated with stage IV disease compared with stage I to III at diagnosis in 1007 patients with stage IV or recurrent lung adenocarcinomas (26% vs. 18%; P = 0.004). Here, EGFR is linked to lung adenocarcinoma.